Few industries provide the same kind of dividend power as big pharma. Between top-selling drugs, cash-cow medications, and up-and-coming blockbusters, pharmaceutical companies like Pfizer (PFE 0.30%) and Johnson & Johnson (JNJ 0.24%) boast the financial fortitude and portfolio firepower to provide for dividend investors for years to come.
Yet in an industry as competitive as this, which are the best stocks for dividend investors to target? Johnson & Johnson's breadth has provided a strong, stable base for dividend investors for the long term, but with the company's medical device business slowing, is this stock slumping out of the top segment of health care stocks?
Not to worry, Johnson & Johnson investors. In the video below, Fool contributor Dan Carroll shows you three big pharma stocks -- including J&J -- that have the potential to transform portfolios in the long run and deliver the types of dividends that will reward investors handsomely for years to come.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
The 3 Most Promising Big Pharma Dividends for the Next 5 Years
NYSE: PFE
Pfizer

AbbVie, Pfizer, and Johnson & Johnson offer up a scintillating mix of growth and stability for dividend investors.
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned




*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.